Early clinical experience with subcutaneous GR43175 in acute migraine: an overview

P Tfelt-Hansen; J Brand; P Dano; A Doenicke; L J Findley; Helle Klingenberg Iversen; D Melchart; H M Sahlender

Early clinical experience with subcutaneous GR43175 in acute migraine: an overview

P Tfelt-Hansen, J Brand, P Dano, A Doenicke, L J Findley, Helle Klingenberg Iversen, D Melchart, H M Sahlender

Institut for Klinisk Medicin

23 Citationer (Scopus)

Abstract

In six European clinics 111 migraine patients were treated in a series of open dose-ranging studies with subcutaneous injections of 1 to 4 mg GR43175, a novel 5-HT 1-like receptor agonist. Response rates after 20-30 min were dose related and rose from 33% with 1 mg to 96% with 4 mg GR43175. Side effects were minor and transient. These promising results warrant confirmation in placebo-controlled double-blind trials. Migraine, treatment, 5-HT agonist, open studies.

Originalsprog	Engelsk
Tidsskrift	Cephalalgia : an international journal of headache
Vol/bind	9 Suppl 9
Sider (fra-til)	73-7
Antal sider	5
ISSN	0333-1024
Status	Udgivet - 1989

Citationsformater

@article{40df097b1802474fb5e1f4b9c48cfe46,

title = "Early clinical experience with subcutaneous GR43175 in acute migraine: an overview",

abstract = "In six European clinics 111 migraine patients were treated in a series of open dose-ranging studies with subcutaneous injections of 1 to 4 mg GR43175, a novel 5-HT 1-like receptor agonist. Response rates after 20-30 min were dose related and rose from 33% with 1 mg to 96% with 4 mg GR43175. Side effects were minor and transient. These promising results warrant confirmation in placebo-controlled double-blind trials. Migraine, treatment, 5-HT agonist, open studies.",

keywords = "Adolescent, Adult, Aged, Dose-Response Relationship, Drug, Female, Humans, Indoles, Injections, Subcutaneous, Male, Middle Aged, Migraine Disorders, Sulfonamides, Sumatriptan",

author = "P Tfelt-Hansen and J Brand and P Dano and A Doenicke and Findley, {L J} and Iversen, {Helle Klingenberg} and D Melchart and Sahlender, {H M}",

year = "1989",

language = "English",

volume = "9 Suppl 9",

pages = "73--7",

journal = "Cephalalgia, Supplement",

issn = "0800-1952",

publisher = "SAGE Publications",

}

TY - JOUR

T1 - Early clinical experience with subcutaneous GR43175 in acute migraine

T2 - an overview

AU - Tfelt-Hansen, P

AU - Brand, J

AU - Dano, P

AU - Doenicke, A

AU - Findley, L J

AU - Iversen, Helle Klingenberg

AU - Melchart, D

AU - Sahlender, H M

PY - 1989

Y1 - 1989

N2 - In six European clinics 111 migraine patients were treated in a series of open dose-ranging studies with subcutaneous injections of 1 to 4 mg GR43175, a novel 5-HT 1-like receptor agonist. Response rates after 20-30 min were dose related and rose from 33% with 1 mg to 96% with 4 mg GR43175. Side effects were minor and transient. These promising results warrant confirmation in placebo-controlled double-blind trials. Migraine, treatment, 5-HT agonist, open studies.

AB - In six European clinics 111 migraine patients were treated in a series of open dose-ranging studies with subcutaneous injections of 1 to 4 mg GR43175, a novel 5-HT 1-like receptor agonist. Response rates after 20-30 min were dose related and rose from 33% with 1 mg to 96% with 4 mg GR43175. Side effects were minor and transient. These promising results warrant confirmation in placebo-controlled double-blind trials. Migraine, treatment, 5-HT agonist, open studies.

KW - Adolescent

KW - Adult

KW - Aged

KW - Dose-Response Relationship, Drug

KW - Female

KW - Humans

KW - Indoles

KW - Injections, Subcutaneous

KW - Male

KW - Middle Aged

KW - Migraine Disorders

KW - Sulfonamides

KW - Sumatriptan

M3 - Journal article

C2 - 2544287

SN - 0800-1952

VL - 9 Suppl 9

SP - 73

EP - 77

JO - Cephalalgia, Supplement

JF - Cephalalgia, Supplement

ER -

Early clinical experience with subcutaneous GR43175 in acute migraine: an overview

Abstract

Fingeraftryk

Citationsformater